Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels

Cellular Oncology

Volumn 34, Issue 5, 2011, Pages 409-417

  Duijkers, Floor A M ^a   Gaal, José ^b   Meijerink, Jules P P ^a   Admiraal, Pieter ^a   Pieters, Rob ^a   De Krijger, Ronald R ^b   Van Noesel, Max M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ALK; Kinase inhibitor; Neuroblastoma; PHOX2B; TAE684

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; TAE 684; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; NVP TAE684; NVP-TAE684; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; SCHWANN CELL; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEUROBLASTOMA; NEURONS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; SCHWANN CELLS; SIGNAL TRANSDUCTION;

EID: 84857217342     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0048-2     Document Type: Article

References (24)

1. H. Caren, F. Abel, P. Kogner, T. Martinsson, High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416, 153-159 (2008)
2. Y. Chen, J. Takita, Y.L. Choi, M. Kato, M. Ohira, M. Sanada, L. Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa, Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008)
3. R.E. George, T. Sanda, M. Hanna, S. Frohling, W. Luther 2nd, J. Zhang, Y. Ahn, W. Zhou, W.B. London, P. McGrady, L. Xue, S. Zozulya, V.E. Gregor, T.R. Webb, N.S. Gray, D.G. Gilliland, L. Diller, H. Greulich, S.W. Morris, M. Meyerson, A.T. Look, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008)
4. I. Janoueix-Lerosey, D. Lequin, L. Brugieres, A. Ribeiro, L. de Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron, D. Valteau-Couanet, T. Frebourg, J. Michon, S. Lyonnet, J. Amiel, O. Delattre, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008)
5. Y.P. Mosse, M. Laudenslager, L. Longo, K.A. Cole, A. Wood, E.F. Attiyeh, M.J. Laquaglia, R. Sennett, J.E. Lynch, P. Perri, G. Laureys, F. Speleman, C. Kim, C. Hou, H. Hakonarson, A. Torkamani, N.J. Schork, G.M. Brodeur, G.P. Tonini, E. Rappaport, M. Devoto, J.M. Maris, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008)
6. T. Iwahara, J. Fujimoto, D. Wen, R. Cupples, N. Bucay, T. Arakawa, S. Mori, B. Ratzkin, T. Yamamoto, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449 (1997)
7. K. Pulford, L. Lamant, S.W. Morris, L.H. Butler, K.M. Wood, D. Stroud, G. Delsol, D.Y. Mason, Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394-1404 (1997)
8. W.G. Dirks, S. Fahnrich, Y. Lis, E. Becker, R.A. MacLeod, H.G. Drexler, Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 100, 49-56 (2002)
9. L. Lamant, K. Pulford, D. Bischof, S.W. Morris, D.Y. Mason, G. Delsol, B. Mariame, Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156, 1711-1721 (2000)
10. I. Miyake, M. Ohira, A. Nakagawara, R. Sakai, Distinct role of ShcC docking protein in the differentiation of neuroblastoma. Oncogene 28, 662-673 (2009)
11. J. Degoutin, N. Brunet-de Carvalho, C. Cifuentes-Diaz, M. Vigny, ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur J Neurosci 29, 275-286 (2009)
12. R. Li, S.W. Morris, Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28, 372-412 (2008)
13. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, G. Inghirami, The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8, 11-23 (2008)
14. R.H. Palmer, E. Vernersson, C. Grabbe, B. Hallberg, Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420, 345-361 (2009)
15. A. Oberthuer, J. Theissen, F. Westermann, B. Hero, M. Fischer, Molecular characterization and classification of neuroblastoma. Future Oncol 5, 625-639 (2009)
16. Y. Osajima-Hakomori, I. Miyake, M. Ohira, A. Nakagawara, A. Nakagawa, R. Sakai, Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167, 213-222 (2005)
17. Y.P. Mosse, A. Wood, J.M. Maris, Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15, 5609-5614 (2009)
18. L. Passoni, L. Longo, P. Collini, A.M. Coluccia, F. Bozzi, M. Podda, A. Gregorio, C. Gambini, A. Garaventa, V. Pistoia, F. Del Grosso, G.P. Tonini, M. Cheng, C. Gambacorti-Passerini, A. Anichini, F. Fossati-Bellani, M. Di Nicola, R. Luksch, Mutationindependent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69, 7338-7346 (2009)
19. A. Motegi, J. Fujimoto, M. Kotani, H. Sakuraba, T. Yamamoto, ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 117, 3319-3329 (2004)
20. S. De Brouwer, K. De Preter, C. Kumps, P. Zabrocki,M. Porcu, E.M. Westerhout, A. Lakeman, J. Vandesompele, J. Hoebeeck, T. Van Maerken, A. De Paepe, G. Laureys, J.H. Schulte, A. Schramm, C. Van Den Broecke, J. Vermeulen, N. Van Roy, K. Beiske, M. Renard, R. Noguera, O. Delattre, I. Janoueix-Lerosey, P. Kogner, T. Martinsson, A. Nakagawara, M. Ohira, H. Caron, A. Eggert, J. Cools, R. Versteeg, F. Speleman, Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16, 4353-4362 (2010)
21. A. Garaventa, S. Parodi, B. De Bernardi, D. Dau, C. Manzitti, M. Conte, F. Casale, E. Viscardi, M. Bianchi, P. D'Angelo, G.A. Zanazzo, R. Luksch, C. Favre, A. Tamburini, R. Haupt, Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 45, 2835-2842 (2009)
22. U. McDermott, A.J. Iafrate, N.S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H.G. Choi, S.L. Smith, L. Dowell, L.E. Ulkus, G. Kuhlmann, P. Greninger, J.G. Christensen, D.A. Haber, J. Settleman, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68, 3389-3395 (2008)
23. I. Janoueix-Lerosey, G. Schleiermacher, O. Delattre, Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29, 1566-1579 (2010)
24. T.R. Webb, J. Slavish, R.E. George, A.T. Look, L. Xue, Q. Jiang, X. Cui, W.B. Rentrop, S.W. Morris, Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9, 331-356 (2009)